Analyzes biomarkers related to 50 types of cancer from a single blood sample Japan is the first overseas market for the company's offering, following its U.S. introduction in 2025 Sold through partner medical institutions July 1, 2026 – Abbott (Abbott Park, Illinois, USA) announced today the launch of Cancerguard, a blood test for Multi-Cancer Early Detection (MCED), in Japan. This makes Japan the first country outside the United States to have the test offered by the company. Cancer remains the leading cause of death in Japan and a significant public health challenge. According to a report from the National Cancer Center (1), approximately 1 in 2 people in Japan will develop cancer in their lifetime, and about 1 in 4 will die from cancer. While Japan has screening programs for breast, colorectal, cervical, lung, and stomach cancers, many cancers are difficult to detect before symptoms appear. Therefore, research into new approaches to complement existing screenings is underway. Cancerguard is intended to complement, not replace, existing cancer screenings, and therefore its provision through medical institutions is mandatory to ensure adequate explanation of the test's purpose and interpretation of results. This test detects biomarkers (DNA and proteins derived from cancer cells) for 50 cancer types and subtypes from a single blood draw, providing information to assist healthcare professionals in their evaluation. Cancerguard is based on approximately 10 years of research and development conducted in collaboration with leading academic research institutions. Multiple clinical studies have been conducted involving over 20,000 participants, including the DETECT-A trial (2), a prospective study evaluating MCED tests. In development studies (3), Cancerguard has reported the following results (test data from specific clinical studies): Specificity of 97.4%, helping to minimize false positives and unnecessary follow-up tests Sensitivity of 64.1% for the targeted cancers